Snbl Enters Into Definitive Agreement To Acquire Satsuma Pharmaceuticals
17/04/2023 24:37
April 17 (Reuters) - Shin Nippon Biomedical Laboratories
Ltd 2395.T :
* SHIN NIPPON BIOMEDICAL LABORATORIES LTD: SNBL ENTERS INTO
DEFINITIVE AGREEMENT TO ACQUIRE SATSUMA PHARMACEUTICALS
* SHIN NIPPON BIOMEDICAL LABORATORIES LTD: TENDER OFFER
ESTIMATED
AT $30.2 MILLION
Source text for Eikon: ID:nTSpp85ce5
Further company coverage: 2395.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon